99Tc-MDP Treatment for Knee Osteoarthritis

• Status: Recruiting
• Trial end date: 2023-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

1. Participants with painful osteoarthritis;

2. The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan;

3. Participants voluntarily participate in the trial, and signed the informed consent.

Exclusion Criteria:

1. Knee joint replacement;

2. Inflammatory arthritis or joint infection of knee;

3. Nervous joint disease;

4. Fracture of joint;

5. Gout arthritis of the knee;

6. Traumatic arthritis.